Dasgupta Kaberi, Di Cesar David, Ghosn Joumana, Rajan Raghu, Mahmud Salaheddin, Rahme Elham
Research Institute, Department of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada.
Cancer J. 2006 Mar-Apr;12(2):130-5.
Prostate cancer is the most common malignancy among men in Western nations. Previous studies indicate that nonsteroidal anti-inflammatory drugs have an inhibitory effect on prostate cancer cells. We evaluated the association between frequent use of nonsteroidal anti-inflammatory drugs and prostate cancer occurrence.
We conducted a nested case-control study using medical administrative databases. All men older than 65 years of age who had filled at least one prescription for nonselective nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors (coxibs), aspirin, or acetaminophen between January 1999 and December 2002 were eligible. Among this group, we identified men who underwent prostate biopsy between January 2000 and June 2002 and did not have a diagnosis of any cancer in the preceding 2-year period. Cases were those with a diagnosis of prostate cancer. Controls were those who did not receive a diagnosis of any cancer. Logistic regression models were used to determine associations between prostate cancer occurrence and frequent exposure (more than 4 months) to nonsteroidal anti-inflammatory drugs/cyclooxygenase-2 inhibitors or aspirin during the prior 2 years in comparison with no exposure to any of these drugs, adjusting for age and prior finasteride use.
We identified 2025 cases and 2150 controls. Older men were at greater risk for developing prostate cancer. Exposure to nonsteroidal anti-inflammatory drugs/cyclooxygenase-2 inhibitors was associated with a reduced likelihood of prostate cancer (odds ratio [OR], 0.71; 95% confidence interval [CI], 0.58-0.86) as was exposure to aspirin (OR, 0.84; 95% CI, 0.74-0.96).
Our results suggest that among men 65 years of age or older, frequent use of nonsteroidal anti-inflammatory drugs/cyclooxygenase-2 inhibitors and use of aspirin are associated with a reduced risk of prostate cancer.
前列腺癌是西方国家男性中最常见的恶性肿瘤。先前的研究表明，非甾体抗炎药对前列腺癌细胞有抑制作用。我们评估了频繁使用非甾体抗炎药与前列腺癌发生之间的关联。
我们使用医疗管理数据库进行了一项巢式病例对照研究。所有在1999年1月至2002年12月期间至少开具过一张非选择性非甾体抗炎药、环氧化酶-2抑制剂（coxibs）、阿司匹林或对乙酰氨基酚处方的65岁以上男性均符合条件。在这组人群中，我们确定了在2000年1月至2002年6月期间接受前列腺活检且在之前两年内未被诊断患有任何癌症的男性。病例为被诊断患有前列腺癌的男性。对照为未被诊断患有任何癌症的男性。使用逻辑回归模型来确定前列腺癌发生与在之前两年内频繁接触（超过4个月）非甾体抗炎药/环氧化酶-2抑制剂或阿司匹林（与未接触任何这些药物相比）之间的关联，并对年龄和先前使用非那雄胺进行了调整。
我们确定了2025例病例和2150例对照。老年男性患前列腺癌的风险更高。接触非甾体抗炎药/环氧化酶-2抑制剂与前列腺癌发生可能性降低相关（优势比[OR]，0.71；95%置信区间[CI]，0.58 - 0.86），接触阿司匹林也是如此（OR，0.84；95% CI，0.74 - 0.96）。
我们的结果表明，在65岁及以上男性中，频繁使用非甾体抗炎药/环氧化酶-2抑制剂和使用阿司匹林与前列腺癌风险降低相关。
